Pfizer Price to Sales Ratio 2010-2023 | PFE
Historical PS ratio values for Pfizer (PFE) over the last 10 years. The current P/S ratio for Pfizer as of April 26, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Pfizer P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-04-26 |
25.40 |
|
2.48 |
| 2023-12-31 |
28.36 |
$10.26 |
2.76 |
| 2023-09-30 |
32.23 |
$12.00 |
2.69 |
| 2023-06-30 |
35.24 |
$13.62 |
2.59 |
| 2023-03-31 |
38.77 |
$16.24 |
2.39 |
| 2022-12-31 |
48.24 |
$17.51 |
2.76 |
| 2022-09-30 |
40.85 |
$17.45 |
2.34 |
| 2022-06-30 |
48.56 |
$17.69 |
2.75 |
| 2022-03-31 |
47.57 |
$16.16 |
2.94 |
| 2021-12-31 |
53.86 |
$14.27 |
3.78 |
| 2021-09-30 |
38.88 |
$12.12 |
3.21 |
| 2021-06-30 |
35.08 |
$9.75 |
3.60 |
| 2021-03-31 |
32.14 |
$8.17 |
3.93 |
| 2020-12-31 |
32.30 |
$7.41 |
4.36 |
| 2020-09-30 |
30.22 |
$5.70 |
5.30 |
| 2020-06-30 |
26.67 |
$6.12 |
4.36 |
| 2020-03-31 |
26.35 |
$6.70 |
3.93 |
| 2019-12-31 |
31.31 |
$7.19 |
4.35 |
| 2019-09-30 |
28.43 |
$7.06 |
4.03 |
| 2019-06-30 |
33.96 |
$7.03 |
4.83 |
| 2019-03-31 |
33.00 |
$6.96 |
4.74 |
| 2018-12-31 |
33.63 |
$6.81 |
4.94 |
| 2018-09-30 |
33.69 |
$8.88 |
3.80 |
| 2018-06-30 |
27.50 |
$8.83 |
3.11 |
| 2018-03-31 |
26.65 |
$8.71 |
3.06 |
| 2017-12-31 |
26.94 |
$8.79 |
3.07 |
| 2017-09-30 |
26.32 |
$8.65 |
3.04 |
| 2017-06-30 |
24.52 |
$8.61 |
2.85 |
| 2016-12-31 |
23.25 |
$8.56 |
2.72 |
| 2016-09-30 |
24.01 |
$8.59 |
2.79 |
| 2016-06-30 |
24.75 |
$8.41 |
2.94 |
| 2016-03-31 |
20.64 |
$8.17 |
2.53 |
| 2015-12-31 |
22.26 |
$7.81 |
2.85 |
| 2015-09-30 |
21.48 |
$7.60 |
2.83 |
| 2015-06-30 |
22.75 |
$7.60 |
2.99 |
| 2015-03-31 |
23.41 |
$7.68 |
3.05 |
| 2014-12-31 |
20.78 |
$7.71 |
2.70 |
| 2014-09-30 |
19.56 |
$7.63 |
2.56 |
| 2014-06-30 |
19.46 |
$7.60 |
2.56 |
| 2014-03-31 |
20.87 |
$7.44 |
2.80 |
| 2013-12-31 |
19.74 |
$7.40 |
2.67 |
| 2013-09-30 |
18.37 |
$7.14 |
2.57 |
| 2013-06-30 |
17.76 |
$6.97 |
2.55 |
| 2013-03-31 |
18.15 |
$7.00 |
2.59 |
| 2012-12-31 |
15.64 |
$7.25 |
2.16 |
| 2012-09-30 |
15.35 |
$6.99 |
2.20 |
| 2012-06-30 |
14.08 |
$7.39 |
1.90 |
| 2012-03-31 |
13.73 |
$7.62 |
1.80 |
| 2011-12-31 |
12.99 |
$7.71 |
1.68 |
| 2011-09-30 |
10.51 |
$8.17 |
1.29 |
| 2011-06-30 |
12.11 |
$8.03 |
1.51 |
| 2011-03-31 |
11.82 |
$8.08 |
1.46 |
| 2010-12-31 |
10.08 |
$8.07 |
1.25 |
| 2010-09-30 |
9.79 |
$8.40 |
1.17 |
| 2010-06-30 |
8.04 |
$8.13 |
0.99 |
| 2010-03-31 |
9.57 |
$7.63 |
1.25 |
| 2009-12-31 |
10.05 |
$7.20 |
1.40 |
| 2009-09-30 |
9.06 |
$7.05 |
1.28 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$143.036B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
